<DOC>
	<DOCNO>NCT01182649</DOCNO>
	<brief_summary>Aim study compare everolimus elute stent sirolimus elute stent comer PCI eligible patient</brief_summary>
	<brief_title>Everolimus Stent Patients With Coronary Artery Disease ( CAD )</brief_title>
	<detailed_description>Compared currently available first-generation drug-eluting stent ( DES ) , second-generation DES design goal improve safety efficacy . Everolimus , sirolimus analogue , release open cell , thin-strut , cobalt-chromium frame . A significant reduction cardiac event note patient everolimus-eluting stent compare paclitaxel-eluting stent . Sirolimus elute stent first available drug elute stent test . Therefore investigator compare safety efficacy everolimus-eluting sirolimus elute stent unselected patient real world practice .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>All patient coronary artery disease eligible percutaneous coronary intervention ( PCI ) Contraindication dual antiplatelet therapy 12 month Known allergy sirolimus everolimus Major surgical procedure plan within 1 month History , symptom , finding suggestive aortic dissection . Participation trial Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Drug Eluting Stents</keyword>
	<keyword>Everolimus Eluting Stent</keyword>
	<keyword>Coronary Angioplasty</keyword>
</DOC>